Fluoroquinolone treatment as a protective factor for 10-day mortality in Streptococcus pneumoniae bacteremia in cancer patients

Imagem de Miniatura
Arquivos
art_FONTANA_Fluoroquinolone_treatment_as_a_protective_factor_for_10day_2021.PDF (953.42 KB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE RESEARCH
Autores
ALMEIDA, S. C. G.
BRANDILEONE, M. C. C.
Citação
SCIENTIFIC REPORTS, v.11, n.1, article ID 3699, 12p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
To evaluate the prognostic factors in adult cancer patients with pneumococcal bacteremia, describe episode features and the phenotypic characteristics of the isolated strains. We evaluated the episodes in patients admitted to a cancer hospital between 2009 and 2015. The outcomes were defined as 48 h mortality and mortality within 10 days after the episode. The variables evaluated were: age, sex, ethnicity, ECOG, Karnofsky score, SOFA, cancer type, metastasis, chemotherapy, radiotherapy, neutropenia, previous antibiotic therapy, community or healthcare-acquired infection, comorbidities, smoking, pneumococcal vaccination, infection site, presence of fever, polymicrobial infection, antimicrobial susceptibility, serotype and treatment. 165 episodes were detected in 161 patients. The mean age was 61.3 years; solid tumors were the most prevalent (75%). 48 h and 10-day mortality were 21% (34/161) and 43% (70/161) respectively. The 48 h mortality- associated risk factors were SOFA and polymicrobial bacteremia; 10-day mortality-associated risk factors were fever, neutropenia, ECOG 3/4, SOFA and fluoroquinolones as a protective factor. Pneumococcal bacteremia presented high mortality in cancer patients, with prognosis related to intrinsic host factors and infection episodes features. Fluoroquinolone treatment, a protective factor in 10-day mortality, has potential use for IPDs and severe community-acquired pneumonia in cancer patients.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/39888
Referências
  1. Anatoliotaki M, 2004, INFECTION, V32, P65, DOI 10.1007/s15010-004-3049-5
  2. [Anonymous], 2016, M100 CLSI
  3. Backhaus E, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1648-2
  4. Biedenbach DJ, 2004, DIAGN MICR INFEC DIS, V50, P59, DOI 10.1016/j.diagmicrobio.2004.05.003
  5. Cardoso NT, 2017, DIAGN MICR INFEC DIS, V87, P281, DOI 10.1016/j.diagmicrobio.2016.11.017
  6. Carratala J, 1998, ARCH INTERN MED, V158, P868, DOI 10.1001/archinte.158.8.868
  7. Castanheira M, 2006, MICROB DRUG RESIST, V12, P91, DOI 10.1089/mdr.2006.12.91
  8. CHOU MY, 1983, CANCER, V51, P1546, DOI 10.1002/1097-0142(19830415)51:8<1546::AID-CNCR2820510832>3.0.CO;2-A
  9. ELTING LS, 1986, MEDICINE, V65, P218, DOI 10.1097/00005792-198607000-00002
  10. Garcia-Vidal C, 2012, J INFECTION, V65, P521, DOI 10.1016/j.jinf.2012.08.015
  11. Grabenstein JD, 2014, VACCINE, V32, P2399, DOI 10.1016/j.vaccine.2014.02.096
  12. Gudiol C, 2016, RESPIROLOGY, V21, P1411, DOI 10.1111/resp.12848
  13. Imran MN, 2005, ANN ACAD MED SINGAP, V34, P426
  14. Kumashi P, 2005, MEDICINE, V84, P303, DOI 10.1097/01.md.0000180045.26909.29
  15. Levin AS, 2003, BRAZ J MED BIOL RES, V36, P807, DOI 10.1590/S0100-879X2003000600017
  16. Marin M, 2014, MEDICINE, V93, P143, DOI 10.1097/MD.0000000000000026
  17. Mufson MA, 2012, AM J MED SCI, V343, P303, DOI 10.1097/MAJ.0b013e31822d9860
  18. Naucler P, 2013, THORAX, V68, P571, DOI 10.1136/thoraxjnl-2012-203106
  19. Rahmel T, 2017, BMC ANESTHESIOL, V17, DOI 10.1186/s12871-017-0376-5
  20. RICHARD V, 1988, EUR J EPIDEMIOL, V4, P242, DOI 10.1007/BF00144760
  21. Rosolem MM, 2012, J CRIT CARE, V27, P301, DOI 10.1016/j.jcrc.2011.06.014
  22. Shelburne SA, 2013, J INFECTION, V66, P136, DOI 10.1016/j.jinf.2012.11.007
  23. Shigayeva A, 2016, CLIN INFECT DIS, V62, P139, DOI 10.1093/cid/civ803
  24. Torres VBL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164537
  25. Tumbarello M, 2009, DIAGN MICR INFEC DIS, V64, P320, DOI 10.1016/j.diagmicrobio.2009.02.008
  26. Vardakas KZ, 2008, CAN MED ASSOC J, V179, P1269, DOI 10.1503/cmaj.080358
  27. Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
  28. Weinberger DM, 2010, CLIN INFECT DIS, V51, P692, DOI 10.1086/655828
  29. WHO, 2011, WHOIVB1109
  30. Wong A, 2010, EPIDEMIOL INFECT, V138, P1804, DOI 10.1017/S0950268810000919
  31. Yuan X, 2012, J CHEMOTHERAPY, V24, P257, DOI 10.1179/1973947812Y.0000000028
  32. Zarco-Marquez S, 2016, REV INVEST CLIN, V68, P221

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/03
Artigos e Materiais de Revistas Científicas - LIM/37
Artigos e Materiais de Revistas Científicas - LIM/47
Carregar mais